ARKK Stock Recent News
ARKK LATEST HEADLINES
ARK Innovation ETF had a strong 2023, but 2024 is off to a rough start. Despite its strong performance in 2023, ARKK saw a lot of outflows last year. I have a favorable view of several of the company's top holdings, although there are a few I am less bullish on.
Global portfolio managers prefer the Information Technology and Healthcare sectors for 2024, per a recent Goldman Sachs survey. ARK Innovation ETF is a tech-heavy active ETF that has been consolidating after a strong 2023, underperforming the S&P 500. ARKK has a high concentration in the top 10 holdings and low diversification across market sectors, posing a risk for investors.
Markets managed to absorb a somewhat hotter-than-expected U.S. consumer inflation reading for December without much drama.
Tela has driven electric vehicles (EVs) into the mainstream, becoming the most popular car in the world in the process. After being bogged down by inflation and high interest rates, the auto market is poised for a recovery, which should spark improved results.
Cathie Wood has been piling back into Tesla stock. Tesla grew vehicle sales by a very respectable 38% in 2023.
Cathie Wood joins CNBC's 'Halftime Report' to discuss the growth rally in her ARKK ETF, where she expects Twilio to go from here, and more.
A rating downgrade highlights the superior performance of an alternative innovation ETF compared to ARKK. The recent rating downgrade brings attention to the potential for higher returns from an alternative innovation ETF instead of ARKK. This news suggests that the alternative innovation ETF has outperformed ARKK, indicating a positive development for investors seeking exposure to innovative companies. The downgraded rating on ARKK suggests that it may not be the best choice for investors looking for strong returns in the innovation sector. Investors should consider reevaluating their investment strategies and explore alternative options, as this rating downgrade could influence market perceptions and trading behaviors.
The Ark Innovation ETF's top five holdings make up almost 40% of the fund. The Vanguard S&P 500 has outperformed the Ark Innovation ETF since its inception.
The first trading day of the New Year is setting up as a challenge to the Santa Rally theory, as stock index futures tilt south and bond yields rise.
Cathie Wood has purchased a large stake in CRISPR Therapeutics for her ARK Invest ETFs. The company won a landmark regulatory approval this year, but analysts think the therapy may get off to a slow start commercially.